Pharmacorp Rx Inc. · TSXV:PCRX
Pharmacorp Rx — Investor Presentation (December 2025)
18 slides from Pharmacorp Rx's investor presentation, Dec 12, 2025
Slide 1: Investor Presentation Q3 2025
Investor Presentation Q3 2025
Slide 2: Disclaimers: Forward-Looking Information and Non-IFRS Financial Measures
Disclaimers: Forward-Looking Information, Prospective Investor Disclaimer, Industry and Market Data and Non-IFRS Financial Measures Forward-Looking Information: This presentation contains “forward-looking information” regarding PharmaCorp within the meaning of applicable Canadian securities legislat
Slide 3: Disclaimers: Prospective Investor, Industry Data and Non-IFRS Measures
Disclaimers: Forward-Looking Information, Prospective Investor Disclaimer, Industry and Market Data and Non-IFRS Financial Measures Prospective Investor Disclaimer: This presentation does not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction. Any o
Slide 4: Pharmacy Ownership Models
PHARMACY OWNERSHIP MODELS Spectrum of Pharmacy Ownership Models Franchised/ Corporate- Corporate- Banner Pure Owned Affiliated Co-ops Independent 1,100+ 2,000+ 1,400+ 900+ 1. Figures shown above represent the number of pharmacies 3
Slide 5: ROFR Without Capital
PHARMACHOICE CANADA’S STRUCTURAL CHALLENGE (PRE-PHARMACORP) 1,100+ Independent Pharmacies and Growing 1,150 1,115 1 1,100 1,075 1,050 1,012 1,000 950 952 40+ ROFR Without Capital New Stores 895 900 Joining PharmaChoice Canada (“PCC”) held the right of first Annually refusal on all member stores but
Slide 6: Company Overview (as of December 11, 2025)
COMPANY OVERVIEW (AS OF DECEMBER 11, 2025) ▪ PharmaCorp Rx (TSXV:PCRX) is a Canadian pharmacy consolidator, currently operating four pharmacies under the PharmaChoice Canada banner ▪ Holds an exclusive right-of-first-refusal to acquire 1,100+ pharmacies under a strategic alliance agreement with PCC
Slide 7: Our Sustainable Competitive Advantage
OUR SUSTAINABLE COMPETITIVE ADVANTAGE Exclusive ROFR on Growing Pipeline: 40–50 PCC Proven 1,100+ Stores +40 New Stores/ Stores Turn Over Ability to Acquire Ann. Added to Annually = Built-In Stores with a PCC Banner Deal Flow Unique Offering 6
Slide 8: Why Pharmacy? A Sector Built for Stability & Growth
A SECTOR BUILT FOR STABILITY & GROWTH Why Pharmacy? Percent of Canadians Aged 65+ 1 19.8% 18.9% Recession-Resilient Sector: 18.0% Essential healthcare spend drives stable cash flows 17.1% 16.4% 15.6% Canada’s Aging Population: Prescription demand accelerates after ages 45+ and 65+ 2014 2015 2016 201
Slide 9: Seller Rationale: Post-Acquisition Value Creation
SELLER RATIONALE Post-Acquisition Value Creation Flexible Exit Options Front Shop Growth Opportunity: Pharmacists focus patient outcomes, leaving the front shop under-managed and under-optimized Our Approach: ▪ Re-energize front shop operations by leveraging PharmaChoice Canada’s Portfolio Exit Plan
Slide 10: Our Differentiated Co-Ownership Model
OUR DIFFERENTIATED CO-OWNERSHIP MODEL Subsidiary Ownership (vs. ParentCo Equity) ▪ Direct Alignment: Pharmacists clearly see how their Pharmacist Labour Market Outlook (2024 – 2033) 1 decisions impact financial results ▪ Tangible Rewards: Financial upside tied directly to their ▪ Pharmacists are pro
Slide 11: Minimum Threshold for Acquisition
MINIMUM THRESHOLD FOR ACQUISITION ~$2mm+ ~$350K+ ~35,000+ Annual Revenue Adj. EBITDA 1 Annual Script Count Funding Staffing Acquisition paid partially or Managing pharmacist in full with PCRX Share with store-level Consideration ownership interest 1. Adjusted EBITDA (Pre-IFRS 16, 4-Wall basis) 10
Slide 12: Q3 Highlights
Q3 HIGHLIGHTS Same Store Script Same Store Sales Adjusted EBITDA 1 Count Growth Growth Q1 3.2% 3.9% $707.4K Q2 3.5% 11.3% $688.0K Q3 7.2% 9.4% $840.6K Q4 1. Adjusted EBITDA (Pre-IFRS 16, 4-Wall basis). See appendix for supporting detail Please note that retail pharmacies experience seasonality, with
Slide 13: Experienced Executive & Governance Team
EXPERIENCED EXECUTIVE & GOVERNANCE TEAM Senior Management Team and Board of Directors ➢ Co-founder of PCRX Alan Simpson ➢ Previously co-founded Hospitality Network Canada and StorageVault Canada (TSX: SVI.T) Executive Chairman, Director ➢ StorageVault is Canada’s largest self-storage company with ov
Slide 14: Appendix
PharmaCorp RA) Appendix
Slide 15: Adjusted EBITDA Reconciliation
ADJUSTED EBITDA RECONCILIATION Q1 Q2 Q3 100% Store-Level Net Income Before Tax 1 525,534 512,688 633,837 + Depreciation & Amortization 187,097 188,277 221,969 + Interest on Long Term Debt 5,565 5,352 5,231 + Lease Interest 8,141 7,893 10,395 +/- Other Adjustments 2 7,300 - - - Actual Lease Payments
Slide 16: Capital Structure (as of November 12, 2025)
CAPITAL STRUCTURE (AS OF NOVEMBER 12, 2025) Common Shares % of Undiluted Total Other Shareholders 1 121,330,931 69.7% Institutions 34,317,400 19.7% Board & Executive Team 2 18,433,328 10.6% Total Shares 174,081,659 100.0% 1. Strong Alignment with PCC Network: ~86% of July 2024 $0.40/share retail rai
Slide 17: Q3 Balance Sheet Highlights
Q3 BALANCE SHEET HIGHLIGHTS In C$ 000’s Assets Liabilities Cash 5,025 Accounts payable and accruals 2,841 Accounts receivable 786 Taxes payable 11 Inventories 2,464 Current portion of credit facility 316 Prepaid expenses and deposits 188 Current portion of lease liabilities 88 Current portion of lon
Slide 18: For More Information, Please Contact Us
18 For More Information, Name: Alan Simpson Phone: +1 (306) 536-3771 Please Contact Us Email: simpsonvideo@sasktel.net
PharmaCorp Rx — Investor Presentation (December 2025) on 6ix